The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

GSK GLAXOSMITHKLINE PLC ORD 25P




 Page 1 of 10

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Time/Date Code Headline Source Impact
07:00 20-Sep-2017 GSK Positive IMPACT results for Trelegy in COPD RNS -0.11% Down
07:00 19-Sep-2017 GSK Trelegy Ellipta: FDA approval in COPD received RNS -0.94% Down
07:00 15-Sep-2017 GSK Trelegy Ellipta: positive opinion from CHMP Europe RNS -2.35% Down
07:00 14-Sep-2017 GSK Unanimous FDA approval for Shingrix in over 50s RNS -2.57% Down
16:07 12-Sep-2017 GSK Director/PDMR Shareholding RNS -1.90% Down
08:57 12-Sep-2017 GSK GSK: phase III results on mepo in COPD in NEJM RNS -1.90% Down
08:08 11-Sep-2017 GSK GSK announce positive results from SLS lung study RNS -1.58% Down
16:02 06-Sep-2017 GSK Director/PDMR Shareholding RNS -1.41% Down
09:43 01-Sep-2017 GSK Total Voting Rights RNS -0.10% Down
16:43 10-Aug-2017 GSK Director/PDMR Shareholding RNS -2.54% Down
10:50 10-Aug-2017 GSK Director/PDMR Shareholding RNS -2.54% Down
09:06 04-Aug-2017 GSK Base prospectus re 15bn EMTN programme RNS -0.11% Down
11:02 01-Aug-2017 GSK Total Voting Rights RNS -0.96% Down
16:03 28-Jul-2017 GSK Director/PDMR Shareholding RNS -3.54% Down
15:51 28-Jul-2017 GSK Director/PDMR Shareholding RNS -3.54% Down
13:22 26-Jul-2017 GSK Director/PDMR Shareholding RNS -5.05% Down
12:41 26-Jul-2017 GSK Director/PDMR Shareholding - Replacement RNS -5.05% Down
11:00 26-Jul-2017 GSK Half-year Report RNS -5.05% Down
13:30 25-Jul-2017 GSK ViiV announces results from NEAT 022 study RNS -4.36% Down
13:30 25-Jul-2017 GSK ViiV announces positive results from DAWNING RNS -4.36% Down

 Page 1 of 10

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address C8 Gsk House, 980 Great West Road, Brentford, TW8 9GS, United Kingdom
Company website http://www.gsk.com
Market cap(in millions)* £ 72,482.95
Listing/Admission to trading 22 May 1972
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
25-Sep-17
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 1,500
SEDOL 0925288
ISIN number GB0009252882



GLAXOSMITHKLINE share news analysis (GSK)